Colin R Green Selected Research

tonabersat

2/2022	Blocking connexin43 hemichannels prevents TGF-β2 upregulation and epithelial-mesenchymal transition in retinal pigment epithelial cells.
12/2020	Tonabersat Inhibits Connexin43 Hemichannel Opening and Inflammasome Activation in an In Vitro Retinal Epithelial Cell Model of Diabetic Retinopathy.
1/2020	Connexin Hemichannel Block Using Orally Delivered Tonabersat Improves Outcomes in Animal Models of Retinal Disease.
10/2019	Targeting connexin hemichannels to control the inflammasome: the correlation between connexin43 and NLRP3 expression in chronic eye disease.
10/2017	Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Colin R Green Research Topics

Disease

29	Inflammation (Inflammations) 01/2022 - 09/2003
9	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2021 - 03/2016
9	Wounds and Injuries (Trauma) 01/2021 - 09/2003
9	Ischemia 09/2020 - 01/2012
8	Spinal Cord Injuries (Spinal Cord Injury) 10/2017 - 05/2008
6	Hypoxia (Hypoxemia) 09/2020 - 02/2012
6	Gliosis 01/2020 - 03/2002
5	Chronic Disease (Chronic Diseases) 06/2022 - 04/2014
5	Retinal Diseases 02/2022 - 03/2016
5	Edema (Dropsy) 10/2017 - 12/2011
4	Fibrosis (Cirrhosis) 03/2021 - 08/2012
4	Seizures (Absence Seizure) 09/2020 - 03/2002
4	Brain Ischemia (Cerebral Ischemia) 09/2020 - 01/2014
4	Reperfusion Injury 01/2018 - 05/2004
4	Optic Nerve Diseases (Optic Neuropathy) 10/2015 - 11/2008
3	Brain Injuries (Brain Injury) 06/2022 - 01/2013
3	Eye Diseases (Eye Disease) 01/2022 - 10/2019
3	Necrosis 01/2021 - 05/2004
3	Macular Degeneration (Age-Related Maculopathy) 01/2020 - 03/2016
3	Neuroinflammatory Diseases 01/2018 - 01/2013
3	Disease Progression 01/2018 - 01/2014
3	Cicatrix (Scar) 10/2016 - 01/2006
3	Glaucoma 03/2016 - 08/2012
2	Hyperglycemia 12/2020 - 11/2017
2	Geographic Atrophy 01/2019 - 01/2019
2	Neuralgia (Stump Neuralgia) 01/2018 - 01/2014
2	Ganglion Cysts (Ganglion) 01/2018 - 03/2012
2	Nervous System Trauma 01/2016 - 02/2012
2	Optic Nerve Injuries 06/2011 - 11/2008
2	Infarction (Infarctions) 01/2006 - 05/2004
1	Chronic Renal Insufficiency 03/2021
1	Retinal Degeneration 02/2021
1	Ureteral Obstruction 01/2020
1	Herpes Zoster 01/2020
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2020
1	Aneurysm (Aneurysms) 01/2020
1	Animal Disease Models 10/2019
1	Pathologic Dilatation (Ectasia) 07/2019
1	Ischemic Stroke 01/2019
1	Type 2 Diabetes Mellitus (MODY) 01/2019
1	Vascular Diseases (Vascular Disease) 01/2019
1	Infections 02/2018
1	Pain (Aches) 01/2018
1	Peripheral Nerve Injuries 01/2018
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2018
1	Hypersensitivity (Allergy) 01/2018
1	Migraine Disorders (Migraine) 10/2017
1	Hypothermia 12/2015
1	Macular Edema 05/2014
1	Pseudophakia 05/2014

Drug/Important Bio-Agent (IBA)

47	Connexin 43 (Connexin43)IBA 02/2022 - 03/2002
32	ConnexinsIBA 06/2022 - 03/2002
17	Peptides (Polypeptides)IBA 09/2020 - 05/2008
15	Retinaldehyde (Retinal)IBA 02/2021 - 08/2010
13	InflammasomesIBA 01/2022 - 01/2016
10	Adenosine Triphosphate (ATP)IBA 03/2021 - 01/2013
8	Proteins (Proteins, Gene)FDA Link 02/2021 - 03/2002
6	CytokinesIBA 01/2021 - 09/2003
5	tonabersatIBA 02/2022 - 10/2017
4	OligodeoxyribonucleotidesIBA 08/2012 - 10/2008
3	SolutionsIBA 01/2022 - 01/2018
3	salicylhydroxamic acid (SHAM)IBA 09/2020 - 01/2012
3	Purinergic Receptors (Receptors, Purine)IBA 01/2020 - 01/2014
2	Coloring Agents (Dyes)IBA 01/2020 - 01/2006
2	NLR ProteinsIBA 01/2019 - 01/2018
2	CalciumIBA 01/2014 - 01/2012
2	Glutamic Acid (Glutamate)FDA Link 01/2013 - 01/2012
1	CollagenIBA 03/2021
1	Caspase 3 (Caspase-3)IBA 01/2021
1	Interleukin-1beta (Interleukin 1 beta)IBA 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	Retinal Pigments (Pigments, Visual)IBA 12/2020
1	gamma-Aminobutyric Acid (GABA)IBA 09/2020
1	6-carboxyfluorescein (carboxyfluorescein)IBA 01/2020
1	Transforming Growth Factor beta1 (TGF beta 1)IBA 01/2020
1	Cadherins (E-Cadherin)IBA 01/2020
1	Evans Blue (Blue, Evans)FDA Link 01/2020
1	IonsIBA 01/2020
1	Tight Junction ProteinsIBA 01/2020
1	NucleotidesIBA 10/2019
1	Leucine (L-Leucine)FDA Link 10/2019
1	Pharmaceutical PreparationsIBA 01/2019
1	Ion Channels (Ion Channel)IBA 01/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2018
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2018
1	Fluorescein-5-isothiocyanate (FITC)IBA 01/2018
1	Small Interfering RNA (siRNA)IBA 11/2016
1	Collagen Type II (Type II Collagen)IBA 10/2016
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 04/2016
1	AcidsIBA 10/2015
1	Ophthalmic Solutions (Eye Drops)IBA 09/2015
1	aquaporin 0IBA 05/2014

Therapy/Procedure

7	Therapeutics 01/2022 - 07/2012
3	Intraventricular Infusions 09/2020 - 01/2014
2	Intravitreal Injections 01/2018 - 10/2015
1	Refractive Surgical Procedures 07/2019
1	Drug Therapy (Chemotherapy) 01/2018
1	Spinal Injections 01/2018
1	Vitrectomy 05/2014